Publikationen in Zusammenarbeit mit Forschern von Uppsala University (9)

2022

  1. A 2B adenosine receptor antagonists rescue lymphocyte activity in adenosine-producing patient-derived cancer models

    Journal for ImmunoTherapy of Cancer, Vol. 10, Núm. 5

  2. Exploring Non-orthosteric Interactions with a Series of Potent and Selective A3Antagonists

    ACS Medicinal Chemistry Letters, Vol. 13, Núm. 2, pp. 243-249

  3. Optimization of 2-Amino-4,6-diarylpyrimidine-5-carbonitriles as Potent and Selective A1Antagonists

    Journal of Medicinal Chemistry, Vol. 65, Núm. 3, pp. 2091-2106

2021

  1. 3,4-Dihydropyrimidin-2(1H)-ones as Antagonists of the Human A2B Adenosine Receptor: Optimization, Structure-Activity Relationship Studies, and Enantiospecific Recognition

    Journal of medicinal chemistry, Vol. 64, Núm. 1, pp. 458-480

  2. Potent and Subtype-Selective Dopamine D2Receptor Biased Partial Agonists Discovered via an Ugi-Based Approach

    Journal of Medicinal Chemistry, Vol. 64, Núm. 12, pp. 8710-8726

2020

  1. Nitrogen-Walk Approach to Explore Bioisosteric Replacements in a Series of Potent A2B Adenosine Receptor Antagonists

    Journal of medicinal chemistry, Vol. 63, Núm. 14, pp. 7721-7739

2019

  1. Trifluorinated Pyrimidine-Based A2B Antagonists: Optimization and Evidence of Stereospecific Recognition

    Journal of Medicinal Chemistry, Vol. 62, Núm. 20, pp. 9315-9330

2017

  1. Enantiospecific Recognition at the A2B Adenosine Receptor by Alkyl 2-Cyanoimino-4-substituted-6-methyl-1,2,3,4-tetrahydropyrimidine-5-carboxylates

    Journal of Medicinal Chemistry, Vol. 60, Núm. 8, pp. 3372-3382

2016

  1. Discovery of Potent and Highly Selective A2B Adenosine Receptor Antagonist Chemotypes

    Journal of Medicinal Chemistry, Vol. 59, Núm. 5, pp. 1967-1983